Trial names are self explanatory

Albumin for SBP

Albumin + Cefotaxime vs Cefotaxime alone

Reduced renal impairement

Reduced mortality

Antibiotics in Cirrhosis with haemorrhage

Ceftriaxone IV reduces infections more than oral norfloxacin

Early TIPS

VH with high rebleeding risk

Early TIPS improves one year survival and reduce rebleed compared to pharmacotherapy

• endoscopy

REDUCe study

Demonstrated feasibility, with preliminary evidence of long-term abdominal drains (LTAD) acceptability, effectiveness and safety and reduction in health resource use.

Primary prophylaxis in SBP

NORFLOCIR trial

norfloxacin did not reduce 6-month mortality in patients with advanced cirrhosis, with >95% of patients included having no history of prior SBP.

In post-hoc analyses, norfloxacin, appeared to increase survival of patients with low ascites fluid protein concentrations.

Long term regular outpatient Human Albumin Solution (HAS) therapy

ANSWER study

Overall 18-month survival was significantly higher in the standard therapy plus HAS  group